Hypertension Treatment in India and UAE | Complete Patient Guide

• Patients with newly diagnosed or poorly controlled hypertension (BP consistently >140/90 mmHg on two or more readings) seeking comprehensive evaluation and optimized medical therapy

• Individuals with suspected secondary hypertension (young patients, resistant to ≥3 medications, with clinical clues such as hypokalemia, adrenal incidentaloma, or renal bruit) requiring specialized investigation including aldosterone-to-renin ratio, renal artery Doppler, 24-hour urinary catecholamines/metanephrines, or overnight dexamethasone suppression test

• Patients with resistant hypertension (blood pressure uncontrolled despite ≥3 antihypertensive agents including a diuretic at optimal doses, with adherence confirmed) who are candidates for renal denervation or baroreflex activation therapy

• Individuals with hypertensive urgency or emergency (BP >180/120 mmHg with or without acute end-organ damage) requiring inpatient parenteral management and monitoring

• Patients with hypertension-associated target organ damage: left ventricular hypertrophy (LVMI >115 g/m² in men, >95 g/m² in women), microalbuminuria (UACR 30–300 mg/g), eGFR <60 mL/min/1.73m², or subclinical atherosclerosis on carotid intima-media thickness (CIMT) assessment

• Required diagnostics prior to treatment initiation: 24-hour Ambulatory Blood Pressure Monitoring (ABPM), fasting lipid panel, HbA1c, serum electrolytes (Na, K, Mg), serum creatinine and eGFR, urine albumin-to-creatinine ratio (UACR), 12-lead ECG, transthoracic echocardiogram (ECHO) for LV mass and function, renal ultrasound with Doppler, and fundoscopy for hypertensive retinopathy grading (Keith-Wagener-Barker classification)

• Contraindications / Special Caution: bilateral renal artery stenosis (contraindication to ACEi/ARBs and renal denervation), pregnancy (requires specialized antihypertensive regimens — labetalol, nifedipine, methyldopa), severe aortic stenosis, eGFR <15 mL/min/1.73m² (limits drug class selection), known allergy to contrast agents (requires premedication for angiographic procedures), and patients with white-coat hypertension confirmed by ABPM (pharmacotherapy not indicated)

LIFESTYLE AND NON-PHARMACOLOGICAL INTERVENTIONS (First-Line for Stage 1 Hypertension, Adjunct for All Stages):

Structured therapeutic lifestyle modification remains the foundation of hypertension management. GAF Healthcare partner centers offer medically supervised programs including the DASH (Dietary Approaches to Stop Hypertension) dietary protocol (targeting sodium intake <2.3 g/day and increased potassium to 3.5–5 g/day), aerobic exercise prescription (150 minutes/week of moderate-intensity activity reduces systolic BP by 5–8 mmHg), weight reduction (1 mmHg systolic reduction per 1 kg lost), alcohol moderation (≤14 units/week men, ≤8 units/week women), and structured smoking cessation programs. These interventions are combined with continuous remote blood pressure monitoring platforms for real-time physician oversight.

PHARMACOLOGICAL MANAGEMENT — STEPPED-CARE ALGORITHM:

Step 1 (Monotherapy or Dual Combination): ACE inhibitors (ramipril, perindopril) or ARBs (telmisartan, olmesartan) are first-line for patients with diabetes, CKD, or high cardiovascular risk. CCBs (amlodipine, lercanidipine) are first-line for elderly patients and those with isolated systolic hypertension. Thiazide-like diuretics (indapamide) are preferred over thiazides (hydrochlorothiazide) for superior cardiovascular outcome data.

Step 2 (Triple Combination — RAS blocker + CCB + Diuretic): The ACE/ARB + CCB + thiazide-like diuretic triple combination is the guideline-recommended regimen and achieves control in 70–80% of patients.

Step 3 (Resistant Hypertension Addition): Low-dose spironolactone (25–50 mg/day) is the most effective fourth-line agent, reducing BP by 20–25/10 mmHg on average in confirmed resistant hypertension. Beta-blockers (bisoprolol, carvedilol) are added in patients with concurrent heart failure or atrial fibrillation. Newer agents include finerenone (non-steroidal MRA), aprocitentan (daridorexant class), and amiloride.

INTERVENTIONAL / DEVICE-BASED THERAPIES FOR RESISTANT HYPERTENSION:

• Catheter-Based Renal Denervation (RDN): A minimally invasive endovascular procedure performed under conscious sedation or light general anesthesia. Using a dedicated catheter system (Symplicity Spyral™ by Medtronic or Paradise™ Ultrasound RDN System by ReCor Medical), radiofrequency or ultrasound energy is delivered circumferentially to the renal artery adventitia to ablate afferent and efferent sympathetic renal nerve fibers. SPYRAL HTN-ON MED and RADIANCE II trials demonstrated sustained systolic BP reductions of 6–9 mmHg compared to sham at 3 months. Procedure time: 45–90 minutes. Hospital stay: 1–2 days.

• Baroreflex Activation Therapy (BAT — Barostim Neo™): An implantable neurostimulation device placed subcutaneously below the clavicle, with a lead surgically attached to the carotid sinus. Electrical stimulation of carotid baroreceptors chronically reduces sympathetic outflow and increases parasympathetic tone, achieving sustained BP reductions of 12–24 mmHg systolic in the BeAT-HF and Rheos Pivotal Trial data. Indicated for resistant hypertension with concomitant HFrEF.

• Renal Artery Stenting: For hypertension caused by hemodynamically significant renal artery stenosis (>70% stenosis with FFR-confirmed ischemia), percutaneous transluminal renal angioplasty (PTRA) with drug-eluting stent placement can cure or substantially improve blood pressure control in appropriately selected patients (fibromuscular dysplasia responds better than atherosclerotic stenosis).

• Adrenal Surgery (Laparoscopic Adrenalectomy): The definitive cure for primary aldosteronism confirmed by adrenal vein sampling (AVS) showing lateralized aldosterone excess. Laparoscopic unilateral adrenalectomy achieves biochemical cure in >98% and clinical hypertension cure/improvement in 80–90% of patients. Performed using a 3–4 port laparoscopic retroperitoneal approach for reduced recovery time (hospital stay: 2–3 days).

• Pheochromocytoma Resection: For catecholamine-secreting adrenal tumors, laparoscopic or robotic-assisted adrenalectomy is performed following 10–14 days of alpha-blockade (phenoxybenzamine or doxazosin) and volume repletion, followed by beta-blockade. Robotic platforms (da Vinci Xi) at GAF Healthcare partner centers enable precise dissection in challenging anatomical locations.

PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel): Patients submit medical records, home blood pressure logs, current medication list, and prior investigation reports through GAF Healthcare's secure online portal. A dedicated case manager assigns a consultant cardiologist or nephrologist who reviews records and issues a preliminary treatment plan within 48 hours. Patients are advised to bring a minimum 4-week supply of current antihypertensive medications (with generic/INN names confirmed), and to continue current therapy without interruption to avoid rebound hypertension during travel. A pre-travel blood pressure target of <160/100 mmHg is required for fitness to fly on arrival.

PHASE 2 — DAY 1 TO DAY 3 (Arrival and Comprehensive Evaluation): On Day 1, patients undergo hospital admission (if inpatient evaluation) or outpatient registration. A comprehensive baseline assessment is completed: 24-hour ABPM placement, fasting bloodwork (renal panel, electrolytes, lipids, HbA1c, aldosterone-renin ratio, plasma metanephrines), urinalysis with UACR, 12-lead ECG, and a detailed clinical examination including fundoscopy. Echocardiography (transthoracic, with tissue Doppler imaging for diastolic function and LV mass index quantification) is performed on Day 1 or 2. Renal Doppler ultrasound and, if indicated, CT adrenal with fine cuts or MRI adrenal are completed by Day 2. A multidisciplinary team (cardiologist, nephrologist, endocrinologist, dietitian) case conference occurs on Day 2–3 to formulate the definitive treatment plan.

PHASE 3 — DAYS 3–7 (Treatment Initiation or Procedure): For medical management optimization: The treating physician adjusts, rationalizes, or initiates antihypertensive therapy based on investigation results, guided by individualized hemodynamic data from the ABPM. For spironolactone initiation, serum potassium and renal function are rechecked at 72 hours. Blood pressure response is assessed with daily readings. For renal denervation: The procedure is performed on Day 3–4 in the cardiac catheterization laboratory. Post-procedure observation occurs for 24 hours with continuous BP telemetry. Discharge on Day 5 with outpatient follow-up on Day 7. For laparoscopic adrenalectomy: Surgery is performed under general anesthesia (Day 4–5). Post-operative electrolytes and aldosterone levels are checked on Days 1 and 2 post-surgery. Oral intake resumes within 24 hours. Hospital discharge by Day 7–8.

PHASE 4 — DAYS 7–21 (In-Country Recovery and Monitoring): All patients remain in the country for a minimum of 7–14 days post-procedure (or post-medication optimization initiation) for supervised blood pressure response assessment. Follow-up clinic visits are scheduled on Days 7, 10, and 14. Anti-hypertensive medications are titrated based on home readings and repeat clinic BP measurements. For post-surgical patients, wound check and staple/suture removal occur at Day 10. Before departure, a formal 'fit-to-fly' assessment is conducted: BP must be stable and below 160/100 mmHg, renal function stable (creatinine within 20% of baseline), potassium in the normal range (3.5–5.0 mEq/L), and no postural hypotension on standing.

PHASE 5 — POST-RETURN FOLLOW-UP (Weeks 4–12): GAF Healthcare facilitates telemedicine follow-up consultations at 4 weeks, 8 weeks, and 12 weeks post-return. Patients upload home blood pressure logs and local laboratory results (renal function, electrolytes) for virtual review by the treating physician. Medication adjustments are communicated in writing through the patient portal with specific dosing instructions and safety monitoring guidance.